Re: Farmas USA
ACTC
Preliminares en principio para enero, finales para junio:
http://clinicaltrials.gov/ct2/show/NCT01344993?spons=advanced+cell+technology&spons_ex=Y&rank=3
Este mes deberían salir de esta otra distrofia de Stargardt:
http://clinicaltrials.gov/ct2/show/NCT01345006?spons=advanced+cell+technology&spons_ex=Y&rank=1
En total salen resultados de uno u otro tipo de 3 estudios en enero, pero el jefe dijo que tendrían para octubre, pero no sé de cuál. Hay muy poca información. Y no hay que olvidar que es un chicharro.
Te paso esto, que creo que lo saqué de una conferencia o un informe anual:
We have observed the persistence of visual acuity gains and the engraftment of the transplanted cells in both the SMD and the AMD patients, which is consistent with what was previously reported on earlier in the trials. The clearance to treat patients with higher doses of RPE cells and patients with greater visual acuity, represents significant milestones in our clinical trials. The DSMB’s dose escalation analysis and approvals to treat patients with better vision is a very important to advancing our trials and allows us to further evaluate and target which patients may benefit the most from the treatment, thereby allowing us to more appropriately defined our patient population and better design the labels for our upcoming studies.
Many patients as you know have reported improvement in their every day lives some having their vision improved from being able to see hand motion only to being able to read parts of an eye chart as well as importantly developing better color recognition, contrast and a low light vision.
Based on what we have seen to-date we are planning to review the data we have with our investigators, consultants, and the DSMB and we’ll evaluate the benefit of terminating the Phase I portion of that trial, which was initially planned to treat patients with 200,000 cell dose and instead it advanced to a new protocol or series of protocols for Phase II studies
ACTC is injecting cells (RPE's) that are terminally differentiated. Yes, they are derived from an hESC, but they are absolutely not stem cells. Terminally differentiated cells do not have any pluripotent capabilities. They don't have the ability to differentiate into any other type of cell. This is the reason that the RPE's are safe. If you inject a stem cell (especially an hESC) into a body, it could do any number of things, and most likely do exactly what you don't want it to do. Thanks for the suggestions. See you on iCell.
Cell differentiation is thus a transition of a cell from one cell type to another and it involves a switch from one pattern of gene expression to another. they are not stem cells but retinal pigmented epithelium cells derived from stem cells into the eyes.
El enlace ese que me pones no dice nada...
«Después de nada, o después de todo/ supe que todo no era más que nada.»
